Her reply is nice but known for quite a while. The question which hasn't been answered is
Why has the B-Cell platform been taken off the slides? You don't do it when trying to sell or outlicence or when it is used in a sponsored trial.
Backburner or not, something had been decided and sh did not get told. At CHM 2 assets are in a similar position and get the hell promoted. But at IMU they get demoted. I ask LC the above question and got the standard reply. And I asked the same during the EGM and we all saw her commitment.
IMO, they gave up on B-Cell. No Prof K., the PD1-Vaxx inventor, mentioned anymore and only the Uni Vienna, Dr Joshua Tobias, is continuing presenting Her-Vaxx. There was or maybe still is a collaboration between Vienna and Pfizer combining B-Cell with mRNA but silence for a while in that regards. If anything positive was on the horizon the insiders would already have acted sp-wise.
CF33 was hailed as a paradigm shift- that ship seems to have sailed and Acer-Cell, despite more delays, could become the first registrated allo CAR-T but honestly, nobody gives a damn about it as it is too complicated and expensive.
If I was wrong then IMU would have been already inundated with offers and $$$$.
IMU Price at posting:
3.8¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)